

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Peramivir for treating influenza [ID828]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • BioCryst Pharmaceuticals (peramivir) • Seqirus (peramivir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • African Health Policy Network • Allergy UK • Asthma UK • British Liver Trust • British Lung Foundation • Cardiovascular Care Partnership • Diabetes UK • Heart UK • Kidney Care UK • Liver4Life • Muslim Council of Britain • National AIDs Trust • National Kidney Federation • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance • Surya Foundation • Terence Higgins Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Clinical Diabetologists • Association of British Neurologists • Association of Respiratory Nurse Specialists • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Society for Antimicrobial Chemotherapy • British Society for Haematology • British Society for Heart Failure 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Health and safety executive • Health protection Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Actavis (oseltamivir) • GSK (zanamivir) • Roche (oseltamivir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Acute Respiratory Infections Group • Breathing Matters • British Association for Lung Research • Infectious Disease Research Network • MRC Clinical Trials Unit • National Institute for Health Research

<ul style="list-style-type: none"> • British HIV Association • Diabetes Specialist Nurses • Faculty of Public Health • Institute of Neurology • National Diabetes Nurse Consultant Group • National Pharmacy Association • Primary Care Diabetes Society • Primary Care Neurology Society • Primary Care Respiratory Society UK • Renal Association • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Society for Public Health • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Vascular Nurses • The Clinical Virology Network • UK Clinical Pharmacy Association • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Windsor, Ascot and Maidenhead CCG • NHS North & West Reading CCG • Welsh Government 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.